2 completed, 1 terminated, 1 unknown. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Completed 1, Terminated 1, Unknown 1 |
Follow Digestive Cancer: new trials by email Literature Review of Digestive Cancer trials Research Report on Digestive Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab CEND-1, Panitumumab, Folfirinox - Colon Cancer, Pancreas Cancer | Phase 1 / Phase 2 | Unknown | Anup Kasi | 50 | 2021-10-20 | 2024-12-17 |
| Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers 5-Fluorouracil, L-Folinic acid, Oxaliplatin - Digestive Cancer | Phase 1 / Phase 2 | Terminated | Institut Cancerologie de l'Ouest | 34 | 2017-05-24 | 2022-04-25 |
| Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer Regorafenib, GEMOX - Digestive Cancer | Phase 1 / Phase 2 | Completed | Institut du Cancer de Montpellier - Val d'Aurelle | 66 | 2014-09-01 | 2026-03-12 |
| A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan S-1, Irinotecan, Oxaliplatin - Digestive Cancer | Phase 1 | Completed | Institut du Cancer de Montpellier - Val d'Aurelle | 24 | 2014-04-01 | 2019-08-22 |
Gastrointestinal Neoplasms (4) · Colonic Neoplasms (1) · Pancreatic Neoplasms (1)
Digestive System Diseases (4) · Digestive System Neoplasms (4) · Gastrointestinal Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Colonic Diseases (1) · Colorectal Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Pancreatic Diseases (1)
Oxaliplatin (4) · Fluorouracil (1) · Gemcitabine (1) · Granulocyte Colony-Stimulating Factor (1) · Irinotecan (1) · Leucovorin (1) · Panitumumab (1) · S 1 (combination) (1) · folfirinox (1) · regorafenib (1)
Institut du Cancer de Montpellier - Val d'Aurelle (2) · Anup Kasi (1) · Institut Cancerologie de l'Ouest (1)
France (3) · United States (1)
Anup Kasi, MD (1)